Cogent Biosciences (COGT) Stock Forecast & Price Target

$4.87 +0.29 (+6.33%)

Closing price 04:00 PM Eastern

Extended Trading

$4.86 0.00 (-0.10%)

As of 05:41 PM Eastern

Cogent Biosciences - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 8 Analyst Ratings

Sell
0

Hold
3

Buy
5

Based on 8 Wall Street analysts who have issued ratings for Cogent Biosciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 8 analysts, 3 have given a hold rating, 4 have given a buy rating, and 1 has given a strong buy rating for COGT.

Consensus Price Target

$14.43
196.27% Upside

According to the 8 analysts' twelve-month price targets for Cogent Biosciences, the average price target is $14.43. The highest price target for COGT is $21.00, while the lowest price target for COGT is $8.00. The average price target represents a forecasted upside of 196.27% from the current price of $4.87.

Get the Latest News and Ratings for COGT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Cogent Biosciences and its competitors.

COGT Analyst Ratings Over Time

Type	Current Forecast 4/15/24 to 4/15/25	1 Month Ago 3/16/24 to 3/16/25	3 Months Ago 1/16/24 to 1/15/25	1 Year Ago 4/16/23 to 4/15/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)	5 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$14.43	$14.43	$14.33	$13.67
Forecasted Upside	196.27% Upside	102.08% Upside	76.52% Upside	110.26% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Remove Ads

COGT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

COGT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Cogent Biosciences Stock vs. The Competition

Type	Cogent Biosciences	Medical Companies	S&P 500
Consensus Rating Score	2.75	2.82	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	196.27% Upside	24,628.24% Upside	26.14% Upside
News Sentiment Rating	Positive News See Recent COGT News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
3/7/2025	Piper Sandler 2 of 5 stars	A. Bratzel Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/7/2025	Scotiabank 5 of 5 stars	Louise Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$17.00	+129.42%
2/27/2025	Robert W. Baird 2 of 5 stars	Joel Beatty Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$10.00 ➝ $8.00	+19.23%
2/26/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Fadia Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
2/25/2025	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral	$11.00	+56.47%
1/14/2025	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Robert Burns Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$17.00 ➝ $14.00	+84.94%
11/14/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$19.00 ➝ $21.00	+112.55%
9/24/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$13.00 ➝ $15.00	+39.28%
2/22/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Berens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 06:17 PM ET.

COGT Forecast - Frequently Asked Questions

: According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Cogent Biosciences is $14.43, with a high forecast of $21.00 and a low forecast of $8.00.
: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cogent Biosciences in the last twelve months. There are currently 3 hold ratings, 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" COGT shares.
: According to analysts, Cogent Biosciences's stock has a predicted upside of 196.27% based on their 12-month stock forecasts.
: Over the previous 90 days, Cogent Biosciences's stock had 1 upgrade by analysts.
: Cogent Biosciences has been rated by research analysts at Needham & Company LLC, Piper Sandler, Robert W. Baird, Scotiabank, and Wedbush in the past 90 days.
: Analysts like Cogent Biosciences less than other "medical" companies. The consensus rating score for Cogent Biosciences is 2.75 while the average consensus rating score for "medical" companies is 2.82. Learn more on how COGT compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:COGT) was last updated on 4/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cogent Biosciences (COGT) Stock Forecast & Price Target